vs

Side-by-side financial comparison of Aurinia Pharmaceuticals Inc. (AUPH) and CANTALOUPE, INC. (CTLP). Click either name above to swap in a different company.

CANTALOUPE, INC. is the larger business by last-quarter revenue ($78.7M vs $77.1M, roughly 1.0× Aurinia Pharmaceuticals Inc.). Aurinia Pharmaceuticals Inc. runs the higher net margin — 273.4% vs -0.1%, a 273.4% gap on every dollar of revenue. On growth, Aurinia Pharmaceuticals Inc. posted the faster year-over-year revenue change (28.8% vs 6.8%). Over the past eight quarters, Aurinia Pharmaceuticals Inc.'s revenue compounded faster (23.8% CAGR vs 7.7%).

Aurinia Pharmaceuticals Inc. is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for autoimmune and kidney diseases. Its lead approved product is Lupkynis for adult active lupus nephritis treatment, with core operations in North America and European markets, focusing on nephrology and rare immunology therapeutic segments.

Cantaloupe, Inc., previously known as USA Technologies Inc., is an American company known for its work with ePort cashless acceptance technology running on its patented ePort Connect service, a PCI compliant services. ePort Connect wirelessly facilitates electronic payment options to consumers with credit, debit, or NFC enabled electronic wallets like Apple Pay and Google Pay while providing operators with both telemetry and machine-to-machine (M2M) services. ePort technology is primarily fou...

AUPH vs CTLP — Head-to-Head

Bigger by revenue
CTLP
CTLP
1.0× larger
CTLP
$78.7M
$77.1M
AUPH
Growing faster (revenue YoY)
AUPH
AUPH
+22.0% gap
AUPH
28.8%
6.8%
CTLP
Higher net margin
AUPH
AUPH
273.4% more per $
AUPH
273.4%
-0.1%
CTLP
Faster 2-yr revenue CAGR
AUPH
AUPH
Annualised
AUPH
23.8%
7.7%
CTLP

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
AUPH
AUPH
CTLP
CTLP
Revenue
$77.1M
$78.7M
Net Profit
$210.8M
$-70.0K
Gross Margin
88.6%
Operating Margin
43.1%
2.0%
Net Margin
273.4%
-0.1%
Revenue YoY
28.8%
6.8%
Net Profit YoY
14651.2%
-101.4%
EPS (diluted)
$1.52
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AUPH
AUPH
CTLP
CTLP
Q4 25
$77.1M
$78.7M
Q3 25
$73.5M
$80.9M
Q2 25
$70.0M
$82.6M
Q1 25
$62.5M
$75.4M
Q4 24
$59.9M
$73.7M
Q3 24
$67.8M
$70.8M
Q2 24
$57.2M
$72.7M
Q1 24
$50.3M
$67.9M
Net Profit
AUPH
AUPH
CTLP
CTLP
Q4 25
$210.8M
$-70.0K
Q3 25
$31.6M
$-919.0K
Q2 25
$21.5M
$6.8M
Q1 25
$23.3M
$49.2M
Q4 24
$1.4M
$5.0M
Q3 24
$14.3M
$3.6M
Q2 24
$722.0K
$2.2M
Q1 24
$-10.7M
$4.7M
Gross Margin
AUPH
AUPH
CTLP
CTLP
Q4 25
88.6%
Q3 25
88.9%
Q2 25
89.8%
Q1 25
86.3%
Q4 24
90.7%
Q3 24
91.1%
Q2 24
84.4%
Q1 24
84.6%
39.6%
Operating Margin
AUPH
AUPH
CTLP
CTLP
Q4 25
43.1%
2.0%
Q3 25
40.5%
2.0%
Q2 25
28.7%
6.3%
Q1 25
35.0%
9.1%
Q4 24
-2.8%
8.4%
Q3 24
17.3%
5.8%
Q2 24
-2.6%
4.9%
Q1 24
-26.3%
6.3%
Net Margin
AUPH
AUPH
CTLP
CTLP
Q4 25
273.4%
-0.1%
Q3 25
42.9%
-1.1%
Q2 25
30.7%
8.3%
Q1 25
37.4%
65.2%
Q4 24
2.4%
6.7%
Q3 24
21.2%
5.0%
Q2 24
1.3%
3.0%
Q1 24
-21.4%
6.9%
EPS (diluted)
AUPH
AUPH
CTLP
CTLP
Q4 25
$1.52
$0.00
Q3 25
$0.23
$-0.02
Q2 25
$0.16
$0.10
Q1 25
$0.16
$0.65
Q4 24
$0.00
$0.07
Q3 24
$0.10
$0.04
Q2 24
$0.01
$0.03
Q1 24
$-0.07
$0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AUPH
AUPH
CTLP
CTLP
Cash + ST InvestmentsLiquidity on hand
$80.2M
$53.0M
Total DebtLower is stronger
$37.7M
Stockholders' EquityBook value
$581.3M
$252.5M
Total Assets
$751.6M
$381.9M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AUPH
AUPH
CTLP
CTLP
Q4 25
$80.2M
$53.0M
Q3 25
$72.9M
$55.0M
Q2 25
$52.9M
$51.1M
Q1 25
$66.1M
$46.3M
Q4 24
$83.4M
$27.7M
Q3 24
$36.6M
$33.1M
Q2 24
$33.3M
$58.9M
Q1 24
$63.9M
$50.2M
Total Debt
AUPH
AUPH
CTLP
CTLP
Q4 25
$37.7M
Q3 25
$38.3M
Q2 25
$38.7M
Q1 25
$39.2M
Q4 24
$37.0M
Q3 24
$37.3M
Q2 24
$37.5M
Q1 24
$38.1M
Stockholders' Equity
AUPH
AUPH
CTLP
CTLP
Q4 25
$581.3M
$252.5M
Q3 25
$365.8M
$251.8M
Q2 25
$335.3M
$251.0M
Q1 25
$350.2M
$240.7M
Q4 24
$377.5M
$190.1M
Q3 24
$388.0M
$186.2M
Q2 24
$364.6M
$181.7M
Q1 24
$359.5M
$178.8M
Total Assets
AUPH
AUPH
CTLP
CTLP
Q4 25
$751.6M
$381.9M
Q3 25
$527.5M
$389.5M
Q2 25
$502.6M
$381.9M
Q1 25
$504.9M
$370.5M
Q4 24
$550.6M
$303.0M
Q3 24
$549.4M
$312.1M
Q2 24
$523.5M
$335.6M
Q1 24
$516.6M
$319.9M
Debt / Equity
AUPH
AUPH
CTLP
CTLP
Q4 25
0.15×
Q3 25
0.15×
Q2 25
0.15×
Q1 25
0.16×
Q4 24
0.19×
Q3 24
0.20×
Q2 24
0.21×
Q1 24
0.21×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AUPH
AUPH
CTLP
CTLP
Operating Cash FlowLast quarter
$45.7M
$3.1M
Free Cash FlowOCF − Capex
$-614.0K
FCF MarginFCF / Revenue
-0.8%
Capex IntensityCapex / Revenue
4.8%
Cash ConversionOCF / Net Profit
0.22×
TTM Free Cash FlowTrailing 4 quarters
$25.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AUPH
AUPH
CTLP
CTLP
Q4 25
$45.7M
$3.1M
Q3 25
$44.4M
$7.0M
Q2 25
$44.2M
$9.4M
Q1 25
$1.3M
$22.4M
Q4 24
$30.1M
$522.0K
Q3 24
$17.0M
$-12.0M
Q2 24
$15.8M
$14.3M
Q1 24
$-18.6M
$14.7M
Free Cash Flow
AUPH
AUPH
CTLP
CTLP
Q4 25
$-614.0K
Q3 25
$3.5M
Q2 25
$4.3M
Q1 25
$18.6M
Q4 24
$-3.8M
Q3 24
$-15.8M
Q2 24
$8.5M
Q1 24
$11.4M
FCF Margin
AUPH
AUPH
CTLP
CTLP
Q4 25
-0.8%
Q3 25
4.4%
Q2 25
5.3%
Q1 25
24.6%
Q4 24
-5.1%
Q3 24
-22.3%
Q2 24
11.7%
Q1 24
16.9%
Capex Intensity
AUPH
AUPH
CTLP
CTLP
Q4 25
4.8%
Q3 25
4.2%
Q2 25
6.2%
Q1 25
5.1%
Q4 24
5.8%
Q3 24
5.4%
Q2 24
7.9%
Q1 24
4.8%
Cash Conversion
AUPH
AUPH
CTLP
CTLP
Q4 25
0.22×
Q3 25
1.41×
Q2 25
2.06×
1.38×
Q1 25
0.06×
0.46×
Q4 24
21.07×
0.10×
Q3 24
1.19×
-3.36×
Q2 24
21.94×
6.47×
Q1 24
3.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AUPH
AUPH

Products$74.2M96%
License Collaboration And Royalty Revenue$2.9M4%

CTLP
CTLP

Transaction Processing$47.9M61%
Subscription Revenue$21.8M28%
Products$9.0M11%

Related Comparisons